Features of the course of the new coronavirus infection COVID-19 in patients with chronic kidney disease

BACKGROUND: CKD is one of the main comorbidities in those who die from COVID-19. Renal injury is the most common nonpulmonary infection of SARS-CoV-2 and has a wide range of manifestations, ranging from mild proteinuria and hematuria to progressive acute kidney injury (AKI) requiring renal replacement therapy (RRT).

THE AIM: to study the features of the course of the new coronavirus infection COVID-19 in patients with chronic kidney disease.

PATIENTS AND METHODS: The study included 79 patients with confirmed new coronavirus infection COVID-19 who hospitalized. The first group consisted of people with a history of CKD (44 people), the second group included people without a history of CKD (35 people). The diagnosis of CKD established based on the calculation of glomerular filtration rate using the CKD-EPI formula. The comorbidity index calculated using two scales: Charlson and CIRS-G. Statistical data analysis carried out using the Statistica 12.0 application package (StatSoft Inc., USA).

RESULTS: Patients with COVID-19 and CKD had a higher comorbidity index: according to the Charlson index in one group of patients the indicator was 7 [5.0-9.0], and in group 2 it was 5 [4.0-6.0] (p<0.001). According to the CIRS-G index, in one group the indicator was 9 [7-11.5], in two group it was 4 [2-6] (p <0.001). Patients in one group had a greater degree of damage to the lung tissue according to MSCT of the OGK; in laboratory tests, the levels of CRP, ferritin, LDH, and d-dimer were higher; leukocytosis with a neutrophil shift in the leukocyte count observed.

CONCLUSION: Patients with a history of chronic kidney disease (CKD) had more severe COVID-19 and higher mortality.

1. Urtaeva KK, Suchkov VN. A case of a new CoVID-19 coronavirus infection in a patient being treated with programmatic hemodialysis. Journal Infectology 2020;12(3):94–98. (In Russ.) doi 10.22625/2072-6732-2020-12-3-94-98

2. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed 2020 Mar 19;91(1):157–160. doi: 10.23750/abm.v91i1.9397

3. Niculae A, Peride I, Nechita AM et al. Epidemiological Characteristics and Mortality Risk Factors Comparison in Dialysis and NonDialysis CKD Patients with COVID-19-A Single Center Experience. J Pers Med 2022 Jun 13;12(6):966. doi: 10.3390/jpm12060966

4. Ministry of Health of Russian Federation. Temporary methodical recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-2019). Version 16 (18.08.2022) (approved by the Ministry of Health of Russia) clause 5.7, page 96

5. Ministry of Health of the Russian Federation. Clinical guidelines «Chronic kidney disease», 2021. paragraph 1.5 p. 19

6. Chen J, Wang W, Tang Y et all. Inflammatory stress in SARSCOV-2 associated Acute Kidney Injury. Int J Biol Sci 2021 Apr 10; 17(6):1497–1506. doi: 10.7150/ijbs.58791

7. Coca A, Burballa C, Centellas-Pérez FJ et all. Outcomes of COVID-19 Among Hospitalized Patients With Non-dialysis CKD. Front Med (Lausanne) 2020 Dec 3;7:615312. doi: 10.3389/fmed.2020.615312

8. Sherbak SG, Kamilova ТА, Golota AS, Vologzhanin DA. Risk factors of the severe course and fatal outcome in COVID-19. Physical and rehabilitation medicine, medical rehabilitation 2022;4(1):14–36. (In Russ.) doi:10.36425/rehab104997

9. Ma-Van-de VD, Zaitsev DN, Filev AP, Mukha NV, Ratsina EV, Vasilenko PV, Vasilenko EA, Fetisova NV. Clinical and laboratory markers of severity of the new coronavirus infection (COVID–19). Siberian Medical Review 2022;(3):40–48. (In Russ.) doi: 10.20333/25000136-2022-3-40-48

10. Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 2006 Jul;13(3):199–204. doi: 10.1053/j.ackd.2006.04.004

11. Basile C, Combe C, Pizzarelli F et all. Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres. Nephrol Dial Transplant 2020 May 1;35(5):737–741. doi: 10.1093/ndt/gfaa069. PMID: 32196116; PMCID: PMC7184437

12. Aboughdir M, Kirwin T, Abdul Khader A, Wang B. Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review. Viruses 2020 May 11;12(5):527. doi: 10.3390/v12050527

13. Terpos E, Ntanasis-Stathopoulos I, Elalamy I et al. Hematological findings and complications of COVID-19. Am J Hematol 2020 Jul;95(7):834–847. doi: 10.1002/ajh.25829

14. Li Q, Ding X, Xia G et al. Eosinopenia and elevated Creactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study. E Clinical Medicine 2020 May 3;23:100375. doi: 10.1016/j.eclinm.2020.100375

15. Stringer D, Braude P, Myint PK et al. The role of C-reactive protein as a prognostic marker in COVID-19. Int J Epidemiol 2021 May 17;50(2):420–429. doi: 10.1093/ije/dyab012

16. Chen N, Zhou M, Dong X at al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020 Feb 15;395(10223):507–513. doi: 10.1016/S0140-6736(20)30211-7

17. Polushin YuS, Shlyk IV, Gavrilova EG, Parshin EV, Ginzburg AM. The Role of Ferritin in Assessing COVID-19 Severity. Messenger of Anesthesiology and resuscitation 2021;18(4):20–28. (In Russ.) doi: 10.21292/2078-5658-2021-18-4-20-28

18. Fan BE, Chong VCL, Chan SSW et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol 2020 Jun;95(6):E131–E134. doi: 10.1002/ajh.25774

19. Zheng Z, Peng F, Xu B et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect 2020 Aug;81(2):e16–e25. doi: 10.1016/j.jinf.2020.04.021

20. ERA-EDTA Council; ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021 Jan 1;36(1):87–94. doi: 10.1093/ndt/gfaa314

21. Pakhchanian H, Raiker R, Mukherjee A et all. Outcomes of COVID-19 in CKD Patients: A Multicenter Electronic Medical Record Cohort Study. Clin J Am Soc Nephrol 2021 May 8;16(5):785–786. doi: 10.2215/CJN.13820820